about
Predictive biomarker discovery through the parallel integration of clinical trial and functional genomics datasetsODM-201: a new-generation androgen receptor inhibitor in castration-resistant prostate cancerHypertension and Angiotensin System Inhibitors in Patients with Metastatic Renal Cell Carcinoma31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part oneRenal cell carcinoma.Tumor growth rate provides useful information to evaluate sorafenib and everolimus treatment in metastatic renal cell carcinoma patients: an integrated analysis of the TARGET and RECORD phase 3 trial data.[Haematological complications of prostatic cancer: 2 cases, one revealing the neoplasia].Microvessel area as a predictor of sorafenib response in metastatic renal cell carcinomaPD-L1 expression in nonclear-cell renal cell carcinoma.A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma.Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?Biomarker-Based Phase II Trial of Savolitinib in Patients With Advanced Papillary Renal Cell Cancer.Comprehensive Molecular Characterization of Papillary Renal-Cell CarcinomaEverolimus Versus Sunitinib Prospective Evaluation in Metastatic Non-Clear Cell Renal Cell Carcinoma (ESPN): A Randomized Multicenter Phase 2 Trial.Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma.Tumoral CD105 is a novel independent prognostic marker for prognosis in clear-cell renal cell carcinomaNivolumab in renal cell carcinoma: latest evidence and clinical potential.Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.How to select targeted therapy in renal cell cancer.Vascular endothelial growth factor-targeted therapy for the treatment of renal cell carcinoma.Vascular endothelial growth factor-targeted therapies in advanced renal cell carcinoma.Current role of diethylstilbestrol in the management of advanced prostate cancer.Neoadjuvant treatment in advanced renal cell carcinoma: current situation and future perspectives.Optimal management of metastatic renal cell carcinoma: current status.Clinical implications of body composition assessment by computed tomography in metastatic renal cell carcinoma.Current role of cabozantinib in metastatic castration-resistant prostate cancer.Long-term complete remission with Ipilimumab in metastatic castrate-resistant prostate cancer: case report of two patients.Axitinib in metastatic renal cell carcinoma.Emerging tyrosine kinase inhibitors for the treatment of renal cancer.Current and future strategies in nonclear-cell metastatic renal cell carcinoma.Diagnosis of Renal Cell Carcinoma: A Clinician's Perspective.Recommendations for the Management of Rare Kidney Cancers.Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.Safety of available treatment options for renal cell carcinoma.ITPR1 protects renal cancer cells against natural killer cells by inducing autophagy.Chemotherapy in hormone-sensitive metastatic prostate cancer: Evidences and uncertainties from the literature.Open-label phase 2 trial of first-line everolimus monotherapy in patients with papillary metastatic renal cell carcinoma: RAPTOR final analysis.
P50
Q21183974-8DBF889B-25D4-40B7-BC9F-B637B9A5042EQ26796568-B8633350-6DBF-4992-9E7D-1B1530846C45Q28066747-61618DEB-A1B5-4FF0-B8AE-25E1F3191526Q28553703-366F1D73-B359-4133-AA2F-7A328A84E6C0Q30235364-354CB31A-DAA4-4C0E-A27F-741742E17745Q30664315-FC5F9FBB-6C3A-4BFD-9797-830E8EA82BB1Q33373883-2D7B8C6B-00E6-4E2B-B1C5-922DDF26D0E5Q34658963-72FB0767-B117-4403-941D-18EAD266D6EDQ34882798-6528CB9F-94DF-48DB-9EEB-A3870C15092EQ35171100-2A1C4BCD-30A2-4927-81BD-7D1C3CC1D345Q36124825-114E913E-E5FC-4F12-85AA-491F3A015F6BQ36132720-F77BD380-590B-40F2-ADC3-209107540532Q36182819-B4E91792-CED2-4C03-AFED-E0E4B077A9C3Q36413322-BA923077-BECD-43EC-8D6A-9B19CA063F63Q36642291-AA1ADA09-4A37-45CD-A7F0-F8242440F08AQ36932702-7A869038-EDD9-44ED-8614-BED458DB6FC7Q37409862-A9C57710-2E5D-4DAA-B9D8-9B1DD2DA8A15Q37681761-843895D8-5CF8-40BB-9B01-0CE5F25BA3CCQ37698611-343CB1C9-240A-4CD7-9345-135C4C7A47E7Q37735587-38C1A277-3C24-4943-9056-E807C1B08FD6Q37799953-C1D02E2C-AEA3-4AD7-9D0D-ADBB7094563AQ37895254-A4F8872F-7250-4A5B-A09F-C1A69837F938Q37901848-187F91EC-F62B-486D-A925-815368F12B24Q38009384-1A888AC4-06E0-4668-9305-BC2C045CFB19Q38068585-6273F8F7-7201-4F81-981C-8FF2F8DFA808Q38097746-7CA6A9FD-B1BC-4B08-A198-68824D8AD5E6Q38176985-694C3E6B-A03A-4AD2-85C6-FAD038353F16Q38317384-C56BD6AE-A39D-444B-82C1-CE3E6276E85CQ38374885-66E8AD24-0C14-4944-9E6B-6715B8A607DEQ38439661-C3058089-8FF0-4262-97CA-7E389136E9FBQ38485779-25FDE2C5-0D11-4DEA-B809-FA82F22342FFQ38543833-1B3912E8-E299-4573-B210-B3F98BBBA79EQ38649882-1025C020-60B0-44D4-BFB6-7EA57AF5D4A1Q38673396-35E8398C-9EFD-4011-B555-217B5205ADB3Q38755164-704FBFC9-0EAD-4A79-8CFA-54511380E8D6Q38761275-2F414275-C1DD-45FC-B1F8-2335A5B58EB8Q38824719-3E7D6C0F-CFB4-40FC-B2C9-CBBF248E2B50Q38949623-D17299DF-F9E6-44A6-B752-FB021BC62300Q38963777-1CFE61DD-B4C5-4CD9-9CCC-6F78CE093452Q38966816-FB9ABC38-40EB-4435-B949-156DFD0FCC7F
P50
description
oncoloog
@nl
name
Laurence Albiges
@ast
Laurence Albiges
@en
Laurence Albiges
@es
Laurence Albiges
@fr
Laurence Albiges
@nl
type
label
Laurence Albiges
@ast
Laurence Albiges
@en
Laurence Albiges
@es
Laurence Albiges
@fr
Laurence Albiges
@nl
altLabel
Laurence Albiges-Sauvin
@fr
prefLabel
Laurence Albiges
@ast
Laurence Albiges
@en
Laurence Albiges
@es
Laurence Albiges
@fr
Laurence Albiges
@nl
P214
P269
P106
P2002
P2038
Laurence_Albiges
P21
P214
P269
P31
P7859
viaf-308309174